Drug reference
Type 2 diabetes mellitus not controlled by metformin and/or a sulfonylurea with either saxagliptin or dapagliflozin ▶BY MOUTH ▶Adult 18–74 years: 5/10 mg once daily ▶Adult 75 years and over: Initiation not recommended
PDF page 755
DUE TO INTERACTIONS ▶Dose of concomitant sulfonylurea may need to be reduced. DOSE EQUIVALENCE AND CONVERSION ▶Dose expressed as x/y mg saxagliptin/dapagliflozin.
PDF page 755
Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (July 2017) that saxagliptin with dapagliflozin 5 mg/10 mg (Qtern ®) is accepted for restricted use within NHS Scotland for the treatment of patients with type 2 diabetes mellitus in combination with metformin when the use of a sulfonylurea is inappropriate, only if: . metformin and/or a sulfonylurea, in combination with dapagliflozin or saxagliptin, do not provide adequate glycaemic control; or . the patient is already being treated with the free combination of dapagliflozin and saxagliptin.
PDF page 755
→Appendix 1: dapagliflozin. saxagliptin
PDF page 755
Manufacturer advises caution in moderate impairment; avoid in severe impairment.
PDF page 755
Dose adjustments Manufacturer advises avoid if eGFR less than 60 mL/minute/1.73 m2 (ineffective).
PDF page 755
There can be variation in the licensing of different medicines containing the same drug. Endocrine system Tablet ▶Qtern (AstraZeneca UK Ltd) Saxagliptin (as Saxagliptin hydrochloride) 5 mg, Dapagliflozin (as Dapagliflozin propanediol monohydrate) 10 mg Qtern 5mg/10mg tablets | 28 tablet P £49.56 DT = £49.56
PDF page 755
Missed doses Manufacturer advises if a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
PDF page 755
5/10 mg once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 755
Initiation not recommended
First-line fragment. Read the complete Indications and Dose section above.
PDF page 755
